(R,S)-AM1241，25MG，A6478-25MG，Sigma

Application

(R,S)-AM1241 has been used as a cannabinoid CB2 agonist:

• to study its inhibitory effect on bone cancer-induced pain and bone loss
• to study the effect of its interaction with 17βestradiol on proliferation activity in primary human osteoblasts
• to evaluate the sites of CB2 mediated antinociception in vivo.

Biochem/physiol Actions

AM1241 acts as an antinociceptive agent in several animal pain models. It has a potential to delay disease progression in amyotrophic lateral sclerosis (ALS) mouse model. Intrathecal, intravenous or intraperitoneal administration of AM1241 reduces hyperalgesia and allodynia in neuropathic rats.
Selective CB₂ cannabinoid receptor agonist